BioSpace News Archive

Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Applied Genetic Technologies Corporation announced the presentation of additional analyses and conclusions from previously reported data from the Company’s ongoing Phase 1/2 study of AGTC-501 at the American Academy of Ophthalmology 2021 Annual Meeting being held today in New Orleans, Louisiana by Dr. Robert Sisk.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced a new, blinded, post-hoc analysis of its Phase 2a BALANCED study of efruxifermin (EFX) in biopsy-confirmed patients with non-alcoholic steatohepatitis (NASH).

Mustang Bio, Inc. announced financial results and recent corporate highlights for the third quarter ended September 30, 2021.

Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today reported third quarter 2021 financial results and provided business highlights.

aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at two upcoming virtual investor conferences in November.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), today announced the presentation of positive clinical data from the open-label portion of its ongoing MAESTRO-NAFLD-1 (non-alcoholic fatty liver disease) study of resmetirom at the AASLD The Liver Meeting®, being held virtually November 12th – 15th, 2021.

Spectral Medical Inc., a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc., announced its financial results for the third quarter ended September 30, 2021, and provided a corporate update.

Oculis S.A., (Oculis) a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to improve the sight and lives of patients, today announces that the first patients have been dosed in its Phase 3 DIAMOND trial evaluating the efficacy and safety of OCS-01 in Diabetic Macular Edema (DME) (DIAMOND – DIAbetic Macular edema patients ON a Drop).

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from the Company’s broad hepatitis B virus (HBV) portfolio focused on achieving a functional cure for chronic HBV infection.